Sight Sciences, Inc. (SGHT): Results of Operations and Financial Condition
Sight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sight Sciences Reports Second Quarter 2026 Financial Results Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Compa
How this was made
The 30-second read
Why it matters
The filing provides concrete operating and financial metrics (revenue, gross margin, cash usage, net loss) and two explicit guidance revisions (revenue up, adjusted OpEx down), plus a regulatory clearance (FDA 510(k) for OMNI Ultra) and reimbursement coverage expansion.
Market read
Traders can update valuation and positioning immediately based on the raised revenue range, reduced adjusted OpEx range, and the added regulatory and reimbursement catalysts.
What to watch
Tariff refunds and non-recurring items boosted gross margin and cash usage metrics; traders may normalize results to assess sustainable profitability and cash burn.
Sight Sciences Reports Second Quarter 2026 Financial Results Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance
Revenue increased 20%, Interventional Dry Eye revenue increased 704%, gross margin expanded, operating expenses declined, net loss improved 63%, and the Company raised full-year revenue guidance while reducing adjusted operating expense guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $23.4 million | – | 20% increase |
| Gross profitGAAP | $21.4 million | – | – |
| Gross marginGAAP | 91% | – | – |
| Gross margin excluding tariff refundsother | 86% | – | – |
| Total operating expensesGAAP | $25.3 million | – | 11% decrease |
| Research and development expensesGAAP | $2.5 million | – | 43% decrease |
| Selling, general, and administrative expensesGAAP | $22.8 million | – | 5% decrease |
| Adjusted operating expensesnon-GAAP | $22.3 million | – | 8% decrease |
| Net lossGAAP | $4.4 million | – | 63% improvement |
| Net loss per shareGAAP | $0.08 | – | – |
| Cash usedother | $5.2 million | – | 28% decrease |
| Cash used excluding one-time itemsother | $1.4 million | – | down 81% |
| Cash and cash equivalentsother | $79.8 million | – | – |
| Total long-term debtother | $40.0 million (excluding unamortized debt discount and debt issuance costs) | – | – |
| Interventional Glaucoma gross marginGAAP | 92% | – | – |
| Interventional Glaucoma gross margin excluding tariff refundsother | 86% | – | – |
| Interventional Dry Eye gross marginGAAP | 85% | – | – |
| Interventional Dry Eye gross margin excluding tariff refundsother | 80% | – | up significantly |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Interventional GlaucomaGrowth was primarily driven by increased volumes. | $20.7 million | – | 8% increase |
| Interventional Dry EyeGrowth was driven primarily by increased volumes and higher average selling prices. | $2.7 million | 98% increase | 704% increase |
full year 2026 outlook
- Revenue$88 million to $92 million
- Operating expenses$92 million to $94 million
- NoteRevenue guidance represents year-over-year growth of 14% to 19%.
- NoteInterventional Glaucoma revenue of $79 million to $81 million, representing growth of 4% to 7%.
- NoteInterventional Dry Eye revenue of $9 million to $11 million, compared to $1.6 million in 2025.
- NoteAdjusted operating expenses guidance represents an increase of 5% to 7% compared to 2025.
What drove it
- Interventional Glaucoma growth was primarily driven by increased volumes.
- Interventional Dry Eye growth was driven primarily by increased volumes and higher average selling prices.
- Lower personnel-related expenses and stock-based compensation contributed to the decline in total operating expenses.
- Interventional Dry Eye gross-margin expansion excluding tariff refunds was primarily due to higher average selling prices.
- The Company added an estimated 4.1 million patient lives following publication of fee schedules from certain insurance plans, increasing total IDE patient lives with access to appropriate reimbursement from approximately 10.4 million to 14.5 million.
- IG coverage expanded with the addition of approximately 25 million commercial covered lives from Aetna.
- The Company received U.S. Food and Drug Administration 510(k) clearance of the OMNI Ultra Surgical System.
Concerns
- Interventional Glaucoma revenue increased 8%, below the 20% increase in total revenue.
- Reported gross margin of 91% included a $1.4 million benefit from tariff refunds.
- Cash usage included a $5.4 million litigation success fee.
- The Company reported a net loss of $4.4 million.
- Total long-term debt was $40.0 million as of June 30, 2026.
What to watch
- Interventional Glaucoma revenue growth toward full-year guidance of $79 million to $81 million.
- Interventional Dry Eye revenue growth toward full-year guidance of $9 million to $11 million and the impact of reimbursement access expansion.
- Sustainability of gross margin excluding tariff refunds.
- Adjusted operating expenses against full-year guidance of $92 million to $94 million.
- Cash usage following the second-quarter non-recurring items and tariff refunds.
- Commercial impact of Aetna coverage and OMNI Ultra clearance.
Balance sheet and cash flow
- Cash and cash equivalents totaled $79.8 million as of June 30, 2026.
- Total long-term debt was $40.0 million (excluding unamortized debt discount and debt issuance costs) as of June 30, 2026.
- Cash used in the second quarter of 2026 totaled $5.2 million.
- Cash usage included $3.8 million of non-recurring items, including a $5.4 million litigation success fee, partially offset by $1.6 million of tariff refunds received.
- Excluding these one-time items, cash usage was $1.4 million.
Analysis
Sight Sciences reported a strong second quarter, with revenue of $23.4 million increasing 20% from $19.6 million in the prior-year period. Growth came from both operating segments. Interventional Glaucoma revenue increased 8% to $20.7 million on higher volumes, while record Interventional Dry Eye revenue increased 704% to $2.7 million on higher volumes and higher average selling prices. IDE revenue also increased 98% from $1.4 million in the first quarter of 2026.
Profitability improved materially. Gross profit was $21.4 million compared with $16.6 million in the prior-year period, while reported gross margin was 91%, including a $1.4 million benefit from tariff refunds. Excluding tariff refunds, gross margin was 86% compared with 85% in the prior-year period. IDE gross margin excluding tariff refunds was 80%, compared with 38% in the prior-year period, primarily due to higher average selling prices.
Operating discipline was evident in lower expenses. Total operating expenses declined 11% to $25.3 million, with research and development expenses declining 43% to $2.5 million and selling, general, and administrative expenses declining 5% to $22.8 million. Adjusted operating expenses were $22.3 million, an 8% decrease. Net loss improved 63% to $4.4 million and net loss per share was $0.08, compared with $0.23 in the second quarter of 2025.
Liquidity remained supported by $79.8 million of cash and cash equivalents, versus $85.0 million as of March 31, 2026, while total long-term debt was unchanged at $40.0 million. Cash used was $5.2 million, including $3.8 million of non-recurring items. Excluding those items, cash usage was $1.4 million. The Company raised full-year 2026 revenue guidance to $88 million to $92 million from $83 million to $89 million and reduced adjusted operating expense guidance to $92 million to $94 million from $93 million to $96 million. Execution against the guided IDE ramp, continued IG volume growth, reimbursement expansion, and gross-margin performance excluding tariff refunds are the principal reported items to monitor.
Management, verbatim
We delivered a strong second quarter, with revenue growth accelerating to 20% year-over-year, and both business segments contributing meaningfully to the robust growth. Our performance reflects the growing interventional mindset across glaucoma and dry eye disease, the strength of our market-leading technologies, and the focus of our experienced commercial teams in partnering with customers to make interventional eye care the new standard of care,
Paul Badawi, Co-Founder and CEO of Sight Sciences
Importantly, we achieved this growth while maintaining strong gross margins and disciplined operating expense and cash management. Based on our year-to-date performance and business momentum, we are raising our 2026 revenue guidance, reducing our adjusted operating expense guidance and we believe we are well positioned for the second half of the year.
Paul Badawi, Co-Founder and CEO of Sight Sciences
Not in the filing
stated, not guessed- GAAP operating income or loss
- Adjusted operating expenses prior-year dollar amount
- Adjusted net income or loss
- Adjusted earnings or loss per share
- Operating cash flow
- Free cash flow
- Tax rate
- Capital returns, including share repurchases and dividends
- Full-year 2026 gross-margin guidance
- Full-year 2026 tax-rate guidance
- Prior-year cash and cash equivalents
- Prior-year total long-term debt
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results plus full-year 2026 guidance updates for Sight Sciences.
Ticker impact
Sight Sciences reported Q2 2026 results, raised full-year 2026 revenue guidance to $88M-$92M, and reduced adjusted OpEx guidance to $92M-$94M.
Likely positive near-term reaction as traders re-rate 2H 2026 growth and margin/cash trajectory implied by the updated guidance.
The filing discloses multiple fresh, decision-relevant datapoints: Q2 revenue growth, record IDE revenue, FDA 510(k) clearance for OMNI Ultra, and explicit full-year guidance changes (revenue up, adjusted OpEx down).
Market effects
Reinforces demand and reimbursement momentum in interventional glaucoma and dry eye, potentially improving sentiment toward small-cap eyecare medtech peers.
Primarily US-focused reimbursement and FDA clearance; limited direct regional spillover beyond US healthcare/medtech sentiment.
Modest global relevance, as the disclosed catalysts are US reimbursement policy and FDA clearance.
Counterpoint
The guidance raise may still leave the company dependent on continued reimbursement expansion and volume execution, with net loss still present in Q2.
Key entities
- issuerSight Sciences, Inc.
Reported Q2 2026 financial results, raised 2026 revenue guidance, reduced adjusted operating expense guidance, and received FDA 510(k) clearance for OMNI Ultra.
- payerAetna Inc.
Expanded coverage for certain implant-free glaucoma procedures, retroactive to July 14, 2026.
- regulatorU.S. Food and Drug Administration (FDA)
Granted 510(k) clearance for the OMNI Ultra Surgical System.
